Active Biotech AB Interim report January - September 2012 LUND, SWEDEN -- (Marketwire) -- 11/09/12 -- - Laquinimod - Teva to initiate a new Phase III study in the US at year-end - milestone payment of USD 5 M received following a submitted application for regulatory approval in Europe - Crohn's Phase II data presented at the UEGW conference - TASQ - biomarker data presented at the ESMO conference - Ipsen to initiate two new clinical Phase II studies: maintenance therapy for prostate cancer and a study of other types of cancer - ANYARA - Phase III study results to be presented Q1 2013 - 57-57 - clinical trial of systemic sclerosis/scleroderma is in progress - ISI - project proceeding as planned - Net sales: SEK 136.4 M (231.3) - Operating loss: SEK 168.7 M (loss 6.2) - Loss after tax: SEK 175.1 M (loss: 1.3) - Loss per share for the period: SEK 2.54 (loss: 0.02) This report is also available at www.activebiotech.com Active Biotech AB Interim report January - September 2012: http://hugin.info/1002/R/1656396/535516.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Active Biotech via Thomson Reuters ONE [HUG#1656396] For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam CFO Tel: +46 (0)46 19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 00
Active Biotech AB Interim report January - September 2012
Press spacebar to pause and continue. Press esc to stop.